A Double-blind, Randomized, Parallel, Active-controlled, Non-inferiority, Phase III Clinical Trial to Compare the Efficacy and Safety of HG-102 Versus Botox ® in Subjects With Moderate to Severe Glabellar Lines

Condition:   Glabellar Lines Interventions:   Drug: Botulinum Toxin Type A Injection [HG-102];   Drug: Botulinum Toxin Type A Injection [Botox] Sponsor:   Hugel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials